Perhaps the most exciting, pioneering work by Dr. Jolanta Grembecka and colleagues has led to the development and validation of inhibitors of the MENIN-MLL interaction as highly promising agents for the treatment of KMT2Ar leukemias (72). This evidence concerns the gene KMT2A and leukemia.